Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2024 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2024 Earnings Call Transcript November 8, 2024Xeris Biopharma Holdings, Inc. beats earnings expectations.
Xeris Biopharma Holdings Inc. (XERS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AIGH Investment Partners Orin Hirschman | 2,185,654 | $6,229,114 | 1.75% | |
| 2. | Renaissance Technologies Jim Simons | 1,598,720 | $4,556,353 | +19% | 0% |
| 3. | Millennium Management Israel Englander | 1,445,699 | $4,120,242 | -15% | 0% |
| 4. | AQR Capital Management Cliff Asness | 1,068,116 | $3,044,131 | -11% | 0% |
| 5. | Redmile Group Jeremy Green | 1,046,587 | $2,982,773 | 0.17% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.25 | 4,515 | Director | 25,200 | 2024-08-12 | Filing | |
| $2.37 | 4,285 | Director | 20,685 | 2024-08-09 | Filing | |
| $1.91 | 5,400 | Director | 16,400 | 2024-05-10 | Filing | |
| $2.16 | 4,500 | Director | 11,000 | 2024-03-14 | Filing | |
| $1.87 | 5,400 | Director | 5,400 | 2023-11-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.42 | 11,228 | Officer | 569,780 | 2022-02-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,011,391 | $23,526,769 | 0% | |
| 2. | 7,086,345 | $16,652,910 | 0% | |
| 3. | 5,641,920 | $13,258,512 | 71.57% | |
| 4. | 3,543,685 | $8,327,660 | 6.85% | |
| 5. | 2,892,077 | $6,797,147 | 0% |
News See All
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2024 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2024 Earnings Call Transcript August 8, 2024Xeris Biopharma Holdings, Inc. beats earnings expectations.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call Transcript
Operator: Hello, everyone, and welcome to the Xeris Biopharma First Quarter 2024 Financial Results Conference Call and Webcast. My name is Seth, and I'll be the operator for your call today.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript
Operator: Hello everyone and welcome to the Xeris fourth quarter and full year 2023 financial results conference call and webcast. My name is Emily and I’ll be coordinating your call today.
5 High Growth Micro-cap Stocks to Buy
3 Wall Street analysts covered Blade Air Mobility, Inc. (NASDAQ:BLDE) over the last three months, and all kept a Buy rating on the stock.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2023 Earnings Call Transcript
Operator: Hello, everyone and welcome to the Xeris Biopharma Third Quarter 2023 Financial Results Call. My name is Bruno. I'll be operating your call today.
Hedge Fund and Insider Trading News: Michael Burry, Chris Rokos, Bill Ackman, Dan Loeb, Nelson Peltz, Lone Pine Capital, LYFT Inc (LYFT), Vicarious Surgical Inc. (RBOT), and More
Rokos Capital Management bought more than $2.7 billion of shares in the Invesco QQQ Trust last quarter, part of a wager on the technology sector.
10 Best Fast Growing Penny Stocks to Buy Now
The second half of 2023 started with a strong optimism on the back of hopes that the long-anticipated recession which everyone was talking about might never realize, thanks to cooling inflation, strong...
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2023 Earnings Call Transcript
Operator: Good morning all. I would like to welcome you all to Xeris Biopharma Second Quarter 2023 Financial Results Call. My name is [Prika], and I will be your moderator for today’s call.
10 Best Medical Stocks Under $5
The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the ...